All Oncology News

Atezolizumab plus Chemotherapy Displays Efficacy, Tolerability in NSCLC with Untreated Brain Metastases

September 10th 2021

Atezolizumab plus carboplatin and pemetrexed yielded a favorable safety and efficacy profile in patients with advanced non-squamous non-small cell lung cancer with untreated brain metastases.

Elranatamab Alone or Plus Lenalidomide Shows Early Efficacy, Safety in Heavily Relapsed Myeloma

September 10th 2021

Elranatamab elicited encouraging responses with a manageable toxicity profile when used alone or in combination with lenalidomide in patients with relapsed/refractory multiple myeloma, with efficacy observed even in those who received prior BCMA-directed therapy or who were triple-class refractory, according to data from the phase 1 MagnetisMM-1 trial.

Rituximab-Bendamustine Combo Induces Superior Outcomes Over Other Regimens in Waldenström Macroglobulinemia

September 10th 2021

Treatment with fixed-duration rituximab plus the chemotherapy bendamustine was associated with more favorable outcomes than the triplet of dexamethasone, rituximab, and cyclophosphamide, as well as bortezomib, dexamethasone, and rituximab in patients with treatment-naïve Waldenström macroglobulinemia.

BMI Is a Significant Predictor for Survival in mCRPC

September 10th 2021

Obese men with metastatic castration-resistant prostate cancer have better disease-specific and overall survival than overweight or normal weight patients.

Cilta-Cel Continues to Yield Deep, Durable Response in Relapsed/Refractory Myeloma

September 10th 2021

A single dose of ciltacabtagene autoleucel continued to elicit early, deep, and durable responses and showcase a manageable safety profile in heavily pretreated patients with multiple myeloma.

Cilta-Cel Emerges as Potential CAR T-Cell Option in Relapsed/Refractory Multiple Myeloma

September 10th 2021

The CAR T-cell therapy ciltacabtagene autoleucel has emerged as a potentially durable treatment strategy for patients with relapsed/refractory multiple myeloma who have progressed on 1 to 3 prior lines of treatment and are refractory to lenalidomide.

Ide-Cel Maintains Clinical Activity With Long-Term Follow-Up in Relapsed/Refractory Multiple Myeloma

September 10th 2021

Idecabtagene vicleucel continued to elicit frequent, deep, and durable responses among patients with heavily pretreated relapsed/refractory multiple myeloma irrespective of whether patients received 3 or at least 4 prior therapies.

Live Broadcast to Explore a Treatment Option for EGFR Exon20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer

September 10th 2021

Gynecologic Oncology Pioneer Franco Muggia Dies at 85

September 10th 2021

Franco Muggia, MD, a fixture at NYU Langone’s Perlmutter Cancer Center and a leader in the study and treatment of patients with gynecologic cancers, died on September 8, 2021. He was 85 years old.

Talquetamab Continues to Impress in Relapsed/Refractory Multiple Myeloma

September 10th 2021

Talquetamab, an off-the-shelf T-cell redirecting, GP3C5D-targeting agent, has continued to show promising clinical activity in patients with relapsed/refractory multiple myeloma, especially when given at the recommended phase 2 dose of 405 µg/kg weekly in subcutaneous formulation.

TP53 and IGHV Status Retain Utility as Prognostic Markers in CLL

September 9th 2021

Historical prognostic markers for chemoimmunotherapy have largely lost their clinically relevance in the context of targeted therapies for patients with chronic lymphocytic leukemia; however, IGHV and TP53 mutational status remain important predictive markers of response, now for novel treatments.

Lurbinectedin/Doxorubicin Misses OS End Point in Relapsed SCLC, But Shows Superior Safety Vs SOC

September 9th 2021

The combination of lurbinectedin and doxorubicin produced comparable efficacy to that of standard-of-care vincristine, cyclophosphamide, and doxorubicin or topotecan in patients with relapsed small cell lung cancer, missing the primary end point of the phase 3 ATLANTIS trial.

Noncovalent BTK Inhibitors, CAR T-Cell Therapy Generate Excitement in CLL

September 9th 2021

Sitting at the forefront of clinical development, pirtobrutinib and lisocabtagene maraleucel have generated significant enthusiasm in chronic lymphocytic leukemia.

Controlling Infections Could Be Key to Improving Survival in CLL

September 9th 2021

Patients with chronic lymphocytic leukemia are at an increased risk for infection whether they are in the premalignant state of monoclonal B lymphocytosis, during active surveillance for those are treatment naïve, or are on active treatment.

Higher Rates of Respiratory Disorders Retrospectively Identified in Polycythemia Vera

September 9th 2021

Estimated 4-year mortality rates were greater than 10% in patients with polycythemia vera and vascular complications led to approximately one-third of these deaths, according to a retrospective analysis of the prospective REVEAL trial (NCT02252159) presented during the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting.

Adjuvant Atezolizumab Improves DFS in Early-Stage NSCLC Across Most Disease Stages and Prior Therapies

September 9th 2021

Adjuvant atezolizumab improved disease-free survival over best supportive care in patients with PD-L1–positive, stage II to IIIA non–small cell lung cancer, with benefit observed across most subgroups analyzed, according to data from an exploratory analysis of the phase 3 IMpower010 trial.

Pirtobrutinib Shows Impressive Efficacy in Previously Treated CLL/SLL

September 9th 2021

Pirtobrutinib, showcased promising efficacy signals across dose levels in previously treated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

KRd-ASCT Improves Long-Term PFS in Multiple Myeloma

September 9th 2021

The effectiveness of this treatment in patients with multiple myeloma may be an option for a patient population who represent an unmet need.

Treatment Strategies Utilizing New Agents and Existing Therapies Can Improve Outcomes in Myelofibrosis

September 9th 2021

Various phase 2 and 3 studies are currently underway utilizing both new and existing treatments in an effort to improve outcomes for patients with myelofibrosis.

Flexible Approaches Could Help to Increase Lung Cancer Clinical Trial Enrollment During COVID-19 Pandemic

September 9th 2021

Flexibilities in time and place were effective strategies to mitigate COVID–19-related patient concerns and to increase participation in international lung cancer clinical trials.